<SEC-DOCUMENT>0001437749-12-005128.txt : 20120516
<SEC-HEADER>0001437749-12-005128.hdr.sgml : 20120516
<ACCEPTANCE-DATETIME>20120516094613
ACCESSION NUMBER:		0001437749-12-005128
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120515
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120516
DATE AS OF CHANGE:		20120516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		12847447

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geo_8k-051512.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>geo_8k-051512.htm</title>
    <!--Licensed to: RDG-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold"> SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<hr style="COLOR: black" align="center" noshade size="2" width="12%">
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of report (Date of earliest event reported):&#160;&#160;May 15, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div>
<hr style="COLOR: black" align="center" noshade size="2" width="12%">
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in Charter)</font><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-52091</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">87-0455038</font></div>
</td>
</tr><tr>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(State or other jurisdiction of</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">incorporation or organization)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Commission File No.)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="25%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(IRS Employee Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1900 Lake Park Drive</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite 380</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Smyrna, Georgia 30080</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Address of Principal Executive Offices)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(678) 384-7220</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Issuer Telephone number)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">[&#160;&#160;] Pre-commencement communications pursuant to Rule 13e-4&#169; under the Exchange Act (17 CFR 240.13(e)-4(c))</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: black" align="left" noshade size="3" width="100%">
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#8220;registrant&#8221;) from time to time with the Securities and Exchange Commission (collectively the &#8220;Filings&#8221;) contain forward looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management.&#160;&#160;When used in the Filings the words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;future&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221; or the negative if these terms and similar expressions as they relate to the registrant or the registrant's management identify forward looking statements.&#160;&#160;Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, operations and results of operations and any businesses that may be acquired by the registrant.&#160;&#160;Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On May 15, 2012 we issued a press release reporting our results of operations for the quarter ended March 31, 2012.&#160;&#160;A copy of the press release is attached to this Current Report.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 72pt"></font>Exhibit 99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 72pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated:&#160;&#160;May 16, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GEOVAX LABS, INC.</font></font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:<font style="DISPLAY: inline">&#160;</font></font></td>
<td valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Mark W. Reynolds</font></td>
<td valign="top" width="12%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark W. Reynolds </font>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!--Licensed to: RDG-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div><font style="FONT-WEIGHT: bold">&#160;</font></div>

<div><font style="FONT-WEIGHT: bold"><img src="logo.jpg" alt=""></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">GeoVax Labs Reports 2012 First Quarter Financial Results</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Data from Phase 2a Preventive HIV Vaccine Trial Expected in Late 2012</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Phase 1/2 Therapeutic Vaccine Trial Patient Enrollment Advancing</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Unprecedented Preclinical Results with Adjuvanted Vaccine &#8211; New Human Trial Opened</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Comments on Gilead Science&#8217;s Truvada&#174; Prevention Submission</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ATLANTA, GA, May 15, 2012 &#8211; </font>GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2012 and provided a business update.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are delighted with recent developments that have strengthened and advanced our HIV/AIDS vaccine program,&#8221; said Chairman of the Board David Dodd. &#8220;Our Phase 1/2 therapeutic vaccine trial continues to enroll patients and we expect full enrollment by the end of 2012. The HIV Vaccine Trials Network (HVTN) continues toward the goal of compiling the data for the Phase 2a trial of our preventive vaccine by the end of 2012 and recently opened a new Phase 1 trial of the next generation of our preventive vaccine, which utilizes granulocyte-macrophase colony-stimulating factor (GM-CSF) as an adjuvant to boost the immune response. We are gratified that the NIH-supported HVTN continues to recognize the potential life-saving value of our vaccine technology and has committed substantial resources toward advancing our clinical progress. Most important, we have a highly competent and dedicated team, focused on excellence in execution related to our ongoing development programs.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Robert T. McNally, PhD, GeoVax President and CEO, remarked, &#8220;We are particularly pleased with the outstanding preclinical results we recently reported for our next generation preventive vaccine, which co-expresses GM-CSF as an adjuvant in the DNA vaccine used to prime the immune system. Our studies demonstrated an unprecedented 90% reduction in per exposure risk of transmission for the E660 strain of SIV (simian HIV) and 72% reduction in per exposure risk of transmission for SIV251, the most potent strain of SIV used in non-human primate models. These are extremely rigorous models, with the primates receiving repeated weekly exposures to SIV of up to 300 times the amount one would expect to see in humans. Our data indicate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. McNally continued, &#8220;On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Comment on Gilead Science&#8217;s Truvada&#174; Prevention Submission</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. McNally also commented on the recent news related to an advisory panel&#8217;s recommendation that the FDA approve Gilead Science&#8217;s submission of their anti-viral medication, Truvada, for prevention of HIV. &#8220;While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax&#8217;s preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Financial Review</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes of Health (NIH). This compares to $893,002 of grant revenue reported for the same period in 2011. As of March 31, 2012, there is approximately $3.3 million in unused IPCAVD grant funds available for use through August 31, 2012 (the end of the original project period).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development (R&amp;D) expenses were $1,072,354 for the three months ended March 31, 2012, compared with $838,467 for the comparable period in 2011. R&amp;D expenses include direct costs funded by the IPCAVD grant, as well as vaccine manufacturing costs and expenses related to the Phase 1/2 clinical trial, being sponsored by GeoVax, of the Company&#8217;s therapeutic HIV vaccine. Costs associated with the Phase 2a clinical trial of GeoVax&#8217;s preventative HIV vaccine, being conducted by the HVTN, are being funded directly by the NIH and are therefore not reflected in GeoVax&#8217;s financial statements. General and administrative (G&amp;A) expenses were $512,818 and $661,813 for the three months ended March 31, 2012 and 2011, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax reported cash balances of $2,240,486 at March 31, 2012, as compared to $1,167,980 at December 31, 2011. Summarized financial information is attached. Further information concerning the Company&#8217;s financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About GeoVax&#8217;s Technology</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax&#8217;s unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax&#8217;s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax&#8217;s vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. In GeoVax&#8217;s second generation vaccine, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines&#8217; safety.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About HIV/AIDS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 9&#189; minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different <font style="FONT-SIZE: 10pt">subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B, and C. GeoVax vaccines are currently designed to function against clade B.</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">For more information, please visit <font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">www.geovax.com</font>.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contact</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Investor Relations Group:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Erika Moran, Investor Relations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Janet Vasquez, Public Relations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(212) 825-3210</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FINANCIAL TABLES FOLLOW</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Condensed Consolidated Statements of Operations Information</font></font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(amounts in thousands, except per share data)</font></font></div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom">&#160;</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Three Months Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -27pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenues</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Grant Revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7pt"></font>854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.85pt"></font>893</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,072</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">838</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">513</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">662</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="70%">&#160;</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,585</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest income</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 2.5pt"></font>(730</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.85pt"></font>(606</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss per common share</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 7pt"></font>(0.04</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.85pt"></font>(0.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Condensed Balance Sheet Information</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(amounts in thousands)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom">&#160;</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dec. 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2012</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,240</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,168</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">393</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">250</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 18.05pt"></font>2,633</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 20.3pt"></font>1,418</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property, net</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">158</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">51</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,837</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,645</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Liabilities and stockholders&#8217; equity</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">510</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">941</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,327</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">704</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,837</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,645</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="70%">&#160;</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="70%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common shares outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.35pt"></font>16,851</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 13.6pt"></font>16,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_[0UB4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``2`````$``0!(`````0`!.$))300-```````$````>#A"24T#\P``
M````"```````````.$))300*```````!```X0DE-)Q````````H``0``````
M```".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&
M```````!`#(````!`%H````&```````!`#4````!`"T````&```````!.$))
M30/X``````!P``#_____________________________`^@`````________
M_____________________P/H`````/____________________________\#
MZ`````#_____________________________`^@``#A"24T$`````````@`!
M.$))300"```````$`````#A"24T$"```````$`````$```)````"0``````X
M0DE-!!0```````0````".$))300,``````NT`````0```'`````G```!4```
M,S````N8`!@``?_8_^``$$I&248``0(!`$@`2```_^X`#D%D;V)E`&2`````
M`?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.
M#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M_\``$0@`)P!P`P$B``(1`0,1`?_=``0`!__$`3\```$%`0$!`0$!````````
M``,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!
M!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($
M!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`
M]50LG*Q<2HW95S**AS9:X,;_`)SRUJX/ZT_XP\BO(MP.BQ6VEQ9;FN`<2YIV
MO;C,=+-K7#;ZUGJ>I_@F?X50Z1]0.H]6+>H_63)N:7@%M!<7WQ^;ZUMN]N/_
M`,2QG_;+U8'+\,1/++@!V'S3/T8#GN1ACCQD;G:$?J]!F_XPOJMB`@9)R7#3
M;0QSONL?Z='_`(*JK?KYF9<'I/0<W+K/%CQZ;?\`/:V^O_IK1?TWZL_5;IUW
M4FX==3,5N\V[=]Q/T6,9=;NLW6/<UC/TFQ9^/A?7+KM(SLGJ7[$IN`?CX6/6
M'O:P_0^T76;'^IM_,_Z%/\TC$8:OA].W%DEU_N8E$Y;J_5OPP'_=9&?[4_Q@
MWN_0]'Q<5IX.1>'Q_6%+VN_Z*(6?XQ;!)MZ51/9K;W$?YTJSTGH?6\#-;?E=
M:MZA06N:_'MK:T:_0>Q[7.VN8Y;9>P.#2X!SN`3J4R4X@U&,#Y1E_P"I%T8$
MCU&8\S'_`+EYL8/U_=]+JF$SR;0X_P#5*0P/KV/^]7#=\<8_P>ND6!];W]0J
MZ4[J72;W-R.FO%]E3#++*VD?:*;V?1_F_P!)^^E&9E(1J`O3Y(IE$1!-R-?U
MD8I_Q@,XR>EW?UZ[F_\`GMZR>NV=?ZC;B?5GJ9QO7SK1=:W!<\3BTAUMK;79
M/\V_(M;LH_XE=EA9E&=ATYM!FG(K;:P^3AN]W\I<U]5GMZGU3JGUJN<&T6O^
MQX!<2`,>HC=8-_MVWVAKO^-]5.A(CBD8Q'!M0K]9^BMG&^$"1/%X_H?I-BKK
M_6<*IC,KZM9%%+&AK6X5E.2&M`AK6U5&GZ/\AJ)5]>OJ_O%699;TZ\F/2S:7
MTG_/<TU?^"+<=D8[`2^UC0UN]Q+@(:?\(?Y'\I,]F-ETEKVLOH?RT@/8X?\`
M2:Y1\4#\T*_ND_\`=\:^I#:5_P!X?][PJQLK%RZA=BW,OJ/%E3@]I_M,+FHJ
MYN_ZG]`R;7Y/2+'=,S6R#?T^S9!(^C;0P^CM_>9L9O0J.M=:Z%G4=/\`K'LR
M<3*?Z6)U>INP;R?95FTCVTO?^^SV?\;^FLJ/M@_(;/[DAPS^G[RN,CYAI^\-
M8O\`_]`75>@97U6ZW1G74.OZ53DLNKN:-P]-KVV>C=_H[V-]K?4_1W+U/"S<
M3/Q:\O#M;?CVC<RQIT(_[ZYOY['?01G-:YI:X`M(@@Z@@K(_YK]/HN=D=+=9
MTJ]YFPXA#:WF-H]7#M;;AO\`ZWH>I_PBGGE&4#CTE'3B_1E_>8<>+VC+@UC(
MWP]1_=:7^,/'NN^K-KZFE[<:VJ^VL3[JV._2<?FM:?4?_45[-&=UK"Q;^A]2
M;A46_I79#:VW.>TCV5M986M9[OYW_"?X-6:Z^J-::LG[/F5N$.(:ZDD<%KJG
M'*KLW?UZEACZEW8KW.Z%U/)Z/58XN?B`-NI#CR:JWN]G^<A$QX1$R`,23&1'
M'#U?O1_]!3(&R1$GB`$A?#+T_P!9S\W/^LG0.K-HR.J?M)CL'+RMCZ65C=16
M^RMOZ/<_^<9^^JK^D?5JGHF'U+KE65U;J?5VBTY%&]]P<]GK.=4QCV5UU8OT
M/^^?X-;N)]4>HMZOC=3ZCU8]2.,RRL56T-:"RUKF6,EEG\O\YCTS/J?U#!W4
M]$ZW?T_!)+F8CJV7MKDEQ90^XA[*_=]!2^[`54P#0XI0!QB7S>GTQ_[ACX)F
M[B2+/")'CX?\:3A8V9U;J>!TGH&9D7X^/FY630_*M::LB[%QV,MIK=O/TLCU
M?L]G\Y_-?X7]+ZM[ZQ_5[I?U:P!USHK/L=^(]C;:=[G5Y-5CV56XM[+7OW[F
MN_U]GIZKOJKDYN"[$ZUU*S.>RUM^'EUUMQ[J+&_G5V5.>U_]IG_HOTH4?4^^
MW*HOZWU6_JU>(X68^.]K:Z@]OT++F5[O7L9^\Y+W86")5$$F4(@\.6_Y<'K3
M[<J(,;)KAD3\E//W=0R>B=+ZI]4:)=EG(;C])!,EV/FG<W7V_P`QNM8^W_36
M,5GH7U<Z;U7.S</J&Z_#Z&YN#AX+G%K!M;NNSK:ZMF^W-NWV[O\`J_T7I]1E
M]`Q,KKN%UJP_IL*M]89$AV[^:<Z?^X^^_9_QW_!JKU3ZK')Z@>J],SK>E=1L
M:&76U@/98UHVM];'L]KWM;]%R'O1(H'@E(<4I_ZS^7_35[4KLCB$30C_`%'$
MP>A8/2/K[3AXLG$NP+7MQWDO%;7/VOI;OW?H'N9OVN_X14.LOL^KF?D?5WIF
M;5C=/ZN6O=NF<'U7>G?M+?8RF]G\W_H_^!_G[>AP/J;=@=3;U=G4K,G/=78S
M(LRF>H'EX:*GL;792ZIE.S^:]1_L_1_HE9P/JCAU8>?3U*P]2R>JDG.R;&AA
M=_H655@O]!F/_@=O\V__`*WZ9]Z`()EQ^F,2*^:0/S^K]U`QRH@1X/43O^C^
M[Z?WG2Z3TK"Z1@58&#6*Z*1`XEQ_.LL(V[K+/SU3^L&)^V,;]CL875W65G*O
MX;576]ESPQT>_)MV>E6QG\UO]:W_`(8O2.BNZ;B4XMF;D9C*&AE8M+6@`?1;
M^A96][6M]OZ9]RMY=N94UIQ:!D$SN:7BN-/;[BUR@NIV#Q&[$CZ=?WO4S$7"
MB*%41\S_`/_1]527RJDDI^JDE\JI)*?J'J5U]'3LJ_&8ZR^JFQ]-;&[G.>&D
MUL8S\]SGKG;;_K<UEU;W.;9C5..^BL6-M=114]WI>K17OMSLK,_1UL9_VALI
MK_PJ\`24^'@H\7#_`(7X,.;BL5Q?X-_7Y7Z#LR_K/L?LKN-]XVU,;7614Z]S
MK]7V^C2[]DX%-;&/?=Z&7U')LI_XFN_.^L]M=9><K&=96(%.,U[C=7CT/]/]
M)1952W*S\NUCWY/I4?J'LOI]Z\$24L?:Z\'_`#=_\)CE[O3BW_K;?X+]$],R
M/K!;U+)&3O`%3ME9KV8[+&BMC6!SZO4O]6WUKZLC'SK_`-7_`$>5CXMWHJ`Z
M[]8BVBQO2WDV,-KL9U;VNV^G8ZNLY.]U-&1Z^,[?5:SZ&7A5?SOK+YY23?U5
MF^'85_B^KY?_`$=/ZWA%7=F_\9^B']6Z\6%K*-[O0>]E@QKZ_5>?596UK;2_
M[`['?73O9E^M]K9=ZE7HJ%O5OK/2QXKPA:"6BA[J[20)R]OVD5?3LN9C8>^R
MNNBO$?G?I6?HOTGSTDC^I\*\=_Y?R_FT?KO&_P`/Y?R^=^F.E9G4<G(S&9M'
MHLI>&T$,>T.;+Y_2W;77N;M9O?7171_H;,AGZ1:2^54E7R</$>';3\FQCXN$
M<6^OYO\`_]DX0DE-!`8```````<`"`````$!`/_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="``````````````````#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!
M9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!
M`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__``!$(`$,`P0,!$0`"$0$#$0'_W0`$`!G_Q`&B````!@(#
M`0`````````````'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'
M`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)
M44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%56
M5QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(
MB8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT
M]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"
M@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"
MTN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F
M]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJ
MNLK:ZOK_V@`,`P$``A$#$0`_`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=->8SF
M%V]12Y//Y?%X/&P`F;(9C(4F,HH0`23+5ULL,$8`'Y8>W88)[AQ%;PN\AX!0
M6/[!4]-33P6R&6XF2.(<2Q"C]IH.BG;Y_F%?!?K>22#>/RW^/V-K85=I<92]
MH[3SF8C$9LX?#8#)93**X/&GPZK_`(]BW;_;OGO=*&QY0W%U/GX$BK_O3*%_
MGT#]Q]Q^0=JK]?SCMR,/+QXV;_>59F_ET4K=_P#/9_E@[1=X!\B)MSU2:KT^
MT^LNTLFA*\:4R%1LZ@Q#7_!%1I/]?8NL_8?W1NR*\N"$>LLT"?R\0G^700O/
M?[VJLP:<RF8^D4$[_P`_#`_GT77<?_"DS^7SAO(N(P/R&W;(M_&<+U_M2C@E
M/^#[@[#PTZ`_XQ>Q';_=J]PY:>-<;;$/G.S'_C$3?X>@W<?><]N8:^#;[G+]
MD"J/^JDJ?X.@9RG_``I\^,4>HX+XX]^9`#]!R]5L/#:OZ:OL,]N%5O\`X%O9
MY!]UKFIP#/S'8)_I5G;_`*QKT03_`'K>4T)%ORWN#_Z9H$_ZR-TA)O\`A4/U
MY-*T6$^'>_<FP-E6?M3$4<I_IJCIMA9,J3_KGVM'W6]P7^WYUM4/_-!_\LB]
M(C]ZS;G/Z'(]T_\`S?C_`,D;=<T_X4NY6L`.+_E][_K02+,G;T\@92+$@0=+
M2B^H@?4^]?\``RQ)7Q?<2T7_`)L@?X;@=;_X*&5_[+VWO&_YO'_);'J?#_PI
M'W82?/\`RZ>S`+K8Q=J5[&W.HV;I)02!]!<7]T/W:;7\/N39?\XE_P"VGJX^
M\Y=_B]LK[\I6_P"V7J<G_"E2CIK'.?`WMG%(#9V3L..HTFY!`%5UGC0;$'ZD
M>ZG[LSM_8^X5@Q_YIG_),W5_^"@1?[?VZW!1_P`U!_EA7IYH_P#A3K\=8'6/
M<_QE[VPSD@,E!D]E920&UR$3(Y#;VLC_`!*^T[_=?YA8?XIS7MTGY3#_``(_
M3\?WJ.7`?\;Y2W*/[&A/^%TZ%S;?_"E'X$YA8QF=D_)+:DCVUMDMA;*KZ:*]
MKEI<+V5D)V`)_$1^GLJN/NR>X<53!<[=*/E+(I_XW"H_GT;V_P!Z+VXEH)[;
M<HF^<4;?\<F8_P`NBS?S@/YL/6W;O\OS:N(^,6?WC2CY/=@9O9%5E<OA,ULG
M,MU]UFF"RN_?X:)O'456,S>XLYB\-)-$[T=;`N5I"SF&>,";V?\`:/=-E]P[
MN7FJW@)VJW24*'25/&N-0AU$54%$5YJ'N6D;4%0>@Q[R>\&T[W[<6D?*ES.%
MW6Y>(LR/$_@V^DSZ0:,5=V2&H[6K(E30CHYW\J^M^"WP4^/^UNAMT=\?'C9/
MRHK*>/-?(K';HW_LO;._J7L7*HF1JNOLS4YW(4%5.>M*:JBPQHH9'@AK:6HD
M"">>=F!/NO'SWSUS!<\P6NP;E-RD"5LF2*1XC`I*B90@(_6(,A8BI#`5T@4'
M'M+)R#R%R];<O77,&VP<WD!KY7FB243L`QA8N0?T01&%!H"I--1:MW6W-W;4
MWC0KE-H[GV]NK&N%9,CMS-8W.4+JPNI6KQE354[!A]+-S[@ZYL[NSD,5Y:R1
M2^CJRG]C`'J=;:\M+V,2V=U'+%ZHRL/VJ2.E#[3]*>O>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K_T-_CW[KW42OKZ'%455DLI6TF-QU!3RU5=7U]3#1T5'2P(9)J
MFJJJAXX*>GAC4LSNP50+D^[QQR2ND42%I&-``"22>``&2?EU222.)'EE<+&H
MJ22``!Q))P`/7JI+Y(_SQ/Y>OQSDR&*_TL2]T[OH/N8WVOT90P;W3[FG)C,,
MN\IJ[$]?(14`I(L>6EGCL;Q&UC+O+?L9[B<Q+'.=I%C9-0^)=-X6#YB.C3'Y
M?I@'UZA[F;WX]N.6VD@&[F_O5J#':+XM"/(RU6$?\Y"1Z=4?=X?\*?\`MW,R
M5N.^.OQVV/LFD8M#1[@[1S>8W[F98B1:KBP>WFV7BL95Z?I')-DHE/U+>YOV
M/[L&RPZ'YAYCN+F6N4MT6)?LUOXCG[0JGJ"M^^]-O<WB)R[RU;VT5,/<.TK_
M`&Z$\-!]A=Q]O1.L1\POYZ7STGFCZIS_`,A<O@,B7ACJ.EMHP]5[,H(W)B:E
MG[`VKB=KT=,IUZ;U^79R/JW!/L9S<F^Q?(2_[MK7;8YQG_&I3<2FGI"S.:_9
M%3H%0\Z>_/N`U-HNMSD@.*VD0MXA7UF54'[93T-VT/\`A/[_`#+N_JREW!\B
M^V]H[+>;3-52=D]G[A[4WQ#));44AV[%N?#U,P5R6UYF(WXOS[)+S[P7MGR^
MO@<N[5//3`\"".VC_:VEJ?\`-OH\L_N[^Z',+>/S'NT$%<GZBXDNI,_T5U+7
M_F[T??K;_A+QTS0Q4LO<7RA[+W?4@H]73]>;/VWL."X-W@BK-RUG8LDL9'&L
MP1L0>`I]@'=/O2;S-K&T<K6T0\FFEDF/YA/!'^'J0MJ^ZILD.AMWYKNI3YK!
M%'"/R+^,?\'1Z]B_\)]_Y9VSOMGRW5^^.QIZ8J14;X[2W?$9F7\U%-L:LV3C
MY@WY4PZ?\/8#O_O">YM[40[I;VJG_?-O$/YR"1OY]#[;_NZ^UUE0S;5<71_X
M=<2G^4;1K_+HV^U?Y6W\N[9JPC#_``[Z+JC3E6BDW/LNBWO,K+^EC/O0[@F=
MA_5F)]A*\]U?<>_J+CG/<*'R25HQ^R/2.AA9>TWMKM]#;<E;?4>;Q+(?VR:S
MT8C`?&7XW;4"#:WQ]Z0VT([>,8#JC8>'":?IH_AV`IM-OQ;V&KCF;F2[K]5S
M!?25_CGE;_"QZ$UORQRU:4^DY>L8J?P01+_@0="K0;;V[BE5,7@<+C44`*E!
MBZ&C50/H%6G@C``]E4ES<2YEN'8_-B?\)Z-8[:VA%(K=%'R4#_`.GKVST_UT
M2%!+$*!R22``/ZDG@>_=>X==^_=>Z:*_;^`RJLF4PF(R2-?4E?C:*L5K_74M
M1#(#?V]'<7$1K%.ZGY,1_@/3,EO;RBDL",/FH/\`A'06Y_XV_'7=8<;HZ#Z6
MW()+^09_JS8V8$E[7UC(X*IU7M^?9I;\R<Q6E/I=_O8J?P3RK_@8=%5QRSRY
M=U^JY?L9?]/!$W^%3UJ&=:['V7_,8_G;8[;/7&T=L8'XD?#[)551MW:FS,#C
M,'L"FV)T]NFHRC#%X/#TE+MV3&]M=Z;@FKID2*)ZK'9>5F#F)C[S!W.^O?;?
MV/DN=RO)9.;]Y0!Y)&9I3+<Q@=SL2Q-O:*%%3VN`!2O6&VV6-E[F>^L=KMMG
M%'R=LKDI'&BK"(K60GM10%`N+QBQH.Y"2:TZO<[@_D6_RZ^Y=T;HWOF.M=[;
M9WEO/-Y;<NY=R[5[5WP:[)Y_.U]1E,OEY:7=>5W5B$JZ_(54DTA2F52[GT_C
MW`^R^_/N1LEM:V4&Z02V<$:QHDEO%1410JJ"BHU%4`#-<<>I\WOV!]M-\N;N
M]N-JGBO)Y&D=X[B8%G=BS,0[.M68DG%,\.B0;F_X36]4X2OJ,Y\>/ESWUU#G
M;M)05N=H\'NZ2ED4$P1+6[2GZMR*Q(Q_5Y&=0;\^QS:_>9W>>,0\Q\H;?>Q^
M="R5'V2>.O\`+H"77W7]G@D,W+7.6XV,HX5"/3_;1^`W\^DE)\"OY\?QJ$=1
M\??GEB^\\'C;_:[<["W379/,U<49#)21X7NK`;OVM0P3`D63-Q%/PP^OM6.?
M_8'F:J<P\@/83-QDA0``^NJV>)O^J1^SI'_K>_>#Y7H_+ON%'N$"\(YG))'I
MIN4E4?E*.FV7^;/_`#:?B25B^;7\OU]W;5Q[E<COW8F+SVVJ5*>+2)ZFMWSM
M:7LWJ^:<*"Z1Q148<&WI'(='M'[1<W@MR-[A>#=M\,,K(Y^SPY!!/_Q_\^FF
M]X/>+DV@Y[]N?'LU-&FA5T'V^)&;B#_CGY='I^.O\_K^7]WE)0XC=V[MR?'K
M=56`AQO<&'6CVV]1J`<T^^]O5&;VY2T(!U"?*/B@5O=01;V!.9/N^>X>Q>)+
M9V<>XVH\[=JO3U,+A)"?D@?[>A]RU]XGVYW\QQ7E[+MMV<4N5I'7T$R%X_S<
MI]G5S&VMT;9WG@\?N;9^XL%NS;>6@6JQ6X-M9?'YW!Y.F;]-1C\MBZBJH*V!
MK</'(RG^ON%;FUNK*>2UO+:2&Y0T9'4JRGT*L`0?M'4W6MW:WL$=U97,<ULX
MJKHP=6'J&4D$?8>GWVQTHZ][]U[K_]':/_F6_P`V[I+^7IB(MK/1CM'Y!;@Q
M39';756+R"4=/A:&H61*'<O8>82.I;`82:9":>ECC>OR&DB-8H==5%+GMG[1
M;U[ARF\,GTG+D;Z7N&6I8CC'"N-;TXDD(E1J-:*8?]T/>'8_;F$68C^LYED3
M5';JU`H.!).]#H0G@`"[T.D4JPT>_EW_`#)/EY\VLQ52]S=I98[0EJC-B^JM
MH/4;9ZSPRZT>GBI]KT50R9BII73]NLRDN0R`N1]P1Q[S>Y0]N^4>28D38=I0
M7M*&>2DEPQ_YJ$=E?X8PB_+K!;G'W(YPYYFD??\`=W-E6HMXR8[=!_S3![Z?
MQ2EV^?1R_@+_`",OE!\RZ#"=D[WD3X_]&Y;PUM%O#>.*JJS>&\,8[QN*O8^Q
M#/CJVMQ]7`VJ'(U\]!0S(PDIWJ@"OL'<_>^'*O)<D^WVO^['?UJ#%&P$<;>D
MTW<`P/%$#L.#:#T-/;[V)YKYVB@W*[IMO+ST*RRJ3+(OK##VDJ1P>0HIXKK'
M6V/\6_Y+WP&^+D&-K\=U'1=N[ZH4@>3?W=BT>^\@U;$M_N\;MJJHX-CX.2*8
MLT,E-C%JXQ8-.Y4-[Q/YI]Z^?^:3+$^[FRV]O]!M:Q+3T9P3*^..IR#Z#AUE
MQRI[(>WO*@BE39Q>[BO^C75)FKZJA`B3/#2@(]3U:%D*_`;/V_797)U6*VUM
M?;&'J\CD:ZJEI<5A,#@L-1R55;654SF"BQV+QE!3M)([%(HHD)-E'N+(TN+R
MX2*-7DNI7``%69F8T`'$EB30>9/4KR26]G;R2RND5K$A))HJHJBI)X`*H%3Y
M`#K4?[W_`)H7SM_F5=[9WXR?RML+N+9?6N"J*B#,]LXPIM[=>;PD52:"7>FX
MMZY00IU1L^>8:\=3TK09RI``9WGE^PAR]V#VMY"]L]AAYG]U)HY]T>E(&[XT
M>E?"2)36XE`^,M^BGI0:SASS![K<_P#NAO\`/RM[30RP;6E=5PM$D=*T\5Y6
M%+:$D?IA?UG]:G0,M)_PG:^96\X(-P]J_/JE_OM5JLV4,47978.BID4-*/[T
M9[<.V,E7N')!=Z5"QYO[T_WC>2[,_3[7[?'Z-<+7Z>+'^D2)P/\`>CU:/[MG
M.UZ/J=V]Q!]<V6I]3-G_`)J/*A/^\CJ2O_"<GY4X-SE]K_/R%<_C;UN$?^!=
M@;?)R=,/-0ZLSC]X9*MQ`-4B_P"40PSR0CUJC$!3I?O)<I2D17?MX3;,:.-5
MNU5.&&DP`-BN"0#PJ.MO]V?G")6DL_<<"Y450Z;A:,,J=0G8KFF0"1QH>MK#
MJVBW?C>LNNL=V%5??;^H-B;1HM\5HJ8ZP5F[Z3;^/@W+5BLACABJA49J.=_*
MJ*LFK4``;>\3-T>SDW/<9-O738-/(8A2E(RY*"GE1:8\NLNMJ2\BVO;8MQ?5
MN"V\8E-:UD"`.:^=6J:^?2[]H>E_7O?NO=>]^Z]U#R&.H,O05N*RM%29+&9&
MEGH<ACZ^GBJZ*NHJJ)H:FDJZ6=)(*FFJ(7*.CJ592001[O'))%(DL3E95(((
M-"",@@C((\CU22..:-XI4#1,"""*@@X((."".(ZT_ME9'-_RE/YV=/U749W/
MX[XI?)MZ''[:Q>4S>5J]N8C:O:=<U-M&H5*^IGHXI.L>U,:V*^\J'DJH,%%/
M(\@^Z<MF+?)#[O>R#;JMO$W-NU`EV5%#M)`*R5T@$^/;D24X&5<#'6&-A)/[
M.^^HVEKF5>4=V("*SL46.X:D5-3$#Z>X!BKQ$39.>MPWWAOUFCU6Y_-E^5Z_
M#[X.=O\`8N,R/\/W]NO&_P"BOJUHIE@K5WQORFK,?%EL>Y(_RS:6WH<AFHP0
M0S8X*1ZO<E>TO*?]<>>MGVZ:/5MT+>//Z>%%1BI_YJ-IC_V_49>[W-W]3.0]
MZW*&33N4R_3V_KXTP*AA_P`TUU2_[3HBO_"=;XGMTK\0<KWWN7&?:;Y^3>>7
M.T3SP^.KI.K]GS9'#[-IRCZFA7-9>HRF35D*I4T531L0="GV//O&\V?OKG&+
ME^WDK9;6A5@.!N)*-*?3L`2/Y%&'GT`/NV<H_N3DR7F&YCI?;K)K4GB+>.JQ
M#U[SKE^8=3Y=;!OO'GK(SKWOW7NO>_=>ZZ(!!!`(((((N"#P00>""/?NO=5Z
M_)?^5?\`!;Y6PU]3V7T/M;$[MKE=CV)UO3Q=>[Y2J?7:OJ\IMV&FHMQU4>LZ
M1EZ7(Q#_`%!L+2+RQ[K<^<IE$VS?Y7LU_P!!F_6BIZ!7J4'_`#3*'Y]1OS3[
M2\@<W"1]TY?B2]8?VT`\&8'U+)0.?^:@<?+JASL3^53_`#&OY:69R?<7\M?O
MS>/:FP:*8Y7/=0SK`-WUM#`T#2P9?KJJ6LV'VN5I865IZ.GI,P`VFCH@_K$^
M;=[L>V_N;#%LWN9R_#:[@PTK<9\,$^:SC]:W^QR\7\34ZQ^W+VC]R_:Z:7>O
M:_F&>[VY3J>VH/$('DT!_1N/M14E_@6N>K&_Y9O\ZOK[YCYVCZ#[TV]2](?*
M2F%1CXL'*U32;+['RN,\J9.DVG_%I),GMS=5,U.YDP5?+-*P0FGJ*AA)%#&W
MN=[([CR9`^_[#<-?<K&A+8,L"M329-/:\9J*3)1<C4JU!:3/:WWRV[G6>/E_
M?[9;#FO("Y$4[+74(]7<DHH=4+U;!TLU"!>G[@?J?>O_TJ@OD5VOO_O+O3M;
MMKM)ZT[^WWOG<&>W+2U[U#38BMJ:^5$V_$E5::EH-N4L<=!2T]E6FI::.%55
M$51U:V#:[#8]CVC:-K4#;[>W1$IP8:0=?S,A)D8_B+$^?7);F'=;_?=]WC>-
MT9CN-S<R.]>*G40(_D(P!&H\E4#RZNP_X3Z?`G8'RG[QWUW9W%A:'=77?QWC
MVO/B-E9:".JPVZ^QMTRY>;;\N=HY1)#E,!M:BV[4U4]%*OBJ:N6D$ODIQ/#+
M"WW@.?=PY3V&PV79IVBW/<_$#2KAHX$TAPAXJ\A8+J&54/0@D$3;]WKV_P!N
MYNY@O][WJ%9MLVSPRL3962=]10N#ADC5"VDX9RE:@$'?#55151%5$10J(H"J
MJJ+*JJ+!54"P`^GO`[CD\>L_.&!PZY>_=>ZHM_X4,=[9[I[^7WDMJ[:K:G'Y
M+OKLG;'4N0JJ-VBJ8]J28W/[TW)`LRD%:?+P;1BQU2OTEI*V6,\,?<[?=WV*
M#>/<.&[N8PT=A;27"@\/$JL<9_VK2:QZ,H/4!_>/WZ?9O;F:TMI"LFX74=NQ
M''PJ-+(*_P!)8]!]58CHP'\FKXM[2^,GP+Z4;%8JFAWKW3M';_=78^?,$0RF
M8RF_<5!GMNXRKJ%#2?9;3VKD*2@@@#>%)4GF51)43,X>]YN:KOFCGW>O$E8V
M%C,]M`GDJQ,58@<-4CAG8\34#@HH(_93E.TY6]O]C\.%1N%]"EU._P")GE4.
MBD\:1QE44<!0GBQJ/G:W\QKX.=(;YS/6G:?R7ZSVAOO;KP19_;%7DJRNR6%J
M*FGBJXJ/*+B*#(14-<::=)&@E99D5U+*+BY'M'MIS[OUA!NFT<JW<^WRUT2!
M:*P!H2NHBHJ"*C%0<XZ/MX]SO;_8-PGVK>.;+.#<8J:XRU64D5`;2#0T(-#F
MA%1GH/8OYM_\MV:6.)/EWU6'E=(T,D^>ACU.P5=<LN$2*)+GEF8*!R2![,?]
M9WW.H3_4N]_WE?\`H+HL'O/[6D@?UVLO]Z8?STXZ$SY??.WH'X9=!Q_(#L?<
MD.=V[GX*).M,+M"KH,MENT\IEL?_`!3#TFSYDJ?X=4XRIQI%7+D6E^S@I")-
M;N\,<I3R=R%S!SKS`>7]MM_#GCJ9WD!5;=5;2QDQ4$-VA`-3-V@<2#?G3G_E
M[D?EX<Q;G<^);R4$"1D,]PS#4JQ9TD%>XN3H5.XG@#KZXS^<G_-Y[Y@J.S?C
M'_+\QN1Z6BJ*B3'5,W5W</9$^5I*:4B:"GWCA=Q;0QFX*N%5T2?PW'J4>X*`
MBWO(6;V8]G]@9=KYG]Q&3>Z#4/&MX=)/K&4E*#T\1QUCK![V>\G,*-NO*WMP
MK['4Z3X-Q-J`_P"&AX@Y]?#0BO5@_P#+D_G4[/\`EYV++\<.]^N)_CQ\EH#7
M4V,V[6SUXVQO7)XB.:;+X/&0YRGI,]M3=U#!32R?PFO^X,D<+^.I>8>#W'ON
M3[)7G)^W?UEY?W(;ERQ@LX"^)$K$!7;0622(D@>*A`!(#*`:]2)[9^^5ESEN
M9Y8YAVP[;S2-05"6\.5EJ61=85XY5`)\)P20"58D4Z,E_,E_FD=-?RZ-HX=-
MQ8RI[%[EWM0U5;L#J7#Y&+&5%7CZ:5Z1]S;MS3TV0_NQM05T;P13"FJ:FMJ(
MY(Z>%UAJ9:<,^VGM7O7N/=SFVE%MLL#`2W#*6`8BHCC4$>)(1FE0JK0LPJH8
M4^YWNOLGMK9P"YB-SO<ZDPVZL%)4&ADD<@^'&#BM&9F[54T8K3"?YP7\YQ<+
M_IK;^7IC!T5XOXJ7_P!"O>8F&V_U_P`8_O)_>[6*#[;U_P`3_AW\/T_N:?'Q
M[FG_`%G/98W'[D'N,W[\KII]1;?'PTZ-&FM?P>+J\JUZA#_7G][Q;?OT^VR?
MN'3JK]-=?!_%KUZJ4SK\+3YTIT#GSZ^2/3_\X'X+O\@>K]N5NPOE+\**V#>'
M9/5=96)D\PG4&[ZK&X7>.?VGFJ:GQDFZ=IX'/P8S(2U;P4\^(BIZE9H(Q54\
MU0=>W_+.\^SO/B\O;I<+<\K;X/#@G`*K]3&"T<<B$GPY&4O'IJ0X=2K$*0I)
M[A\S[+[S\@MS'M5LUMS9L1\2>`D,WTTI"R21.`/$C5@DFJBF,HP906!;8\_E
M??*Y/F1\*>F^W:_(+7[YHL,-@=J7=6J4['V3%3XK.5U:B%E@FW32?:YM(P3X
MX,G&#R"/>-GNCRG_`%,YVWG9XX]-@S^-!_S0E[D`_P!)F,_-#UDU[5<W?UUY
M&V3>9'!W!4\&X^4\7:Y/^GQ(/Z+CK7Y_G.[TS_SN_F0_&_\`ES]<Y=H]O[!R
MF,3?M?2R+)2XG=F]J.EW/OG<>1C.JDJZ3K#J3&Q5NIB6IW?(1$`Z@<A?96R@
MY"]MN9?<C<8O\9N$8Q`\6CB)2)!7_?\`<MIQQ"J>L=/>Z]N/<#W-Y8]M-MF_
MQ:W=?&(X+),`\KFG^^+5=6>!9AT-/:G\[3>D>\\7\0/Y2_QH3N^AZMP>/V-@
M=X3[=W7O3"56WMF45%M^GFV3LO9E7B:T;0Q%+2Q119K(UR05"V?[=8C'+*2;
M3['V/T,O.'NYS.;&2Z<RM&'CC8/(2Y$LL@8>*Q-3%&C,O`M6H![N_OK?_7Q<
MF^T'*WU\=K&(DD*22*5B`0&**,J?"6E!+(ZJW$+2C$(=V_SOOYEGQH@R>U?F
MA\4<?UAD-T83*CKOL.BZSW;M[^'[BAHY)L5428G<^Z:W:/8N%BR<44.1HJ+(
M8JLAI)W=:A95C5S>U]CO;+F4I><D\V-=QPR+XT)F1P4)HPU)&LL+$?`[1NA8
M`$4)Z)KKWV]T.6`]GSQR@MI+-&W@S"!T(<"JG0\C13*#0.BR1N%)(-0.K'_Y
M;WSC^7_\Q_X>]J;TV_F>H>JOD'UIV)6[6P&;J-BY;.=9[RIFVWB]P8F@W1MR
M7<S9S`R3SUSTL]?05LGA31.M+,4>&2./<KD;DSVWYQVBTG@O;OEN[MA(R>*J
M3Q_J,C%)/#T-A0P5TR:J6&&$E^V7/G.ON9R7O-Y!/96?,UI<F-'\)GMY?TTD
M421^)K3+:2R.:`!@IRI0_P#+D_FZ=M]F?)KL+X1_/G:6S^I?D'B,[68?857@
ML96[9Q&>SV)#C*;#RE-D\YG*5\UD:9%KL%74L_V>8IF,<1:1Z-JM=[D^T&S[
M9RQM_/'M]=SWG+CQAI0[!V5&^&92J*=`/9,K#5$XSC5I0>V?O'O.Z<T[CR)[
MB6<%GS(DA6(HI17=<M"P9W&LKWPNITRIPSIU+;^;'_-HW;\1=Z]=?&3XK;:V
M[V;\I^P,CA)<CA\MB\GN>AVABMP5,-'M7`C`8/)XNLR.^]]5E3&U'2F8FGHM
M,KPM]Y2-[0^T?M'9\WV6Y<T<V74MKRI;JP5E98S(R"LCZV5@L,*@ZV`.I^T'
MM;I=[P>\%[R=?;;RKRC:Q77-MPR%E96D$:N:1IH5E+33,>Q2PTIW$=R=6J_&
M'&?)>CZNP>0^5V[-C9WMW-T-'DL_@.M]K?W>VALBIJ(%DEVS0UL^:SU;N:JQ
M[OHJ*\RQP2RJ?#&(P'>*.:I>5WW:>/E&SN(]F1BJ-/)KDE`/]H0$0(&XA*$@
M?$2>$M\J1<TIM%O)SA>6\F]2*&=8(]$41/\`H:DN[.5X%R0"?A4#B8OV&^A-
MUJU?\*#_`(-;1V[LO#_S$.F:<=?=P=>[YV;3=FY/;+'"2[G@RN7I,;L[?_FH
M3%)#O[;&[CCZ5:V(+455/5(\LA:CA]Y4_=XYZN[B^E]NMZ/U.SW$$A@5^[00
MI,D&:UBECU]O!6':!K;K$_[QO(5G;6$7N3L@^FWFVGB$[)VZPS`13XI2:*31
MW\64]Q.A>B>?\/I_S,O^?#4W_H$9#_ZU^Q5_K&>V?_1__P"JH_S]!/\`U^?<
MW_IGO^J1_P`W7__3/%_.9_DF=@3[]WY\N_B)MJJWG@MX5V1WCVWTU@J9ZK=F
M!W+72R5VX=W["Q4"O4[FP>>K9)*NKQE.KU]%5RNU/'-2/XZ+,;V:][-N;;[#
ME#G"[$%S`HCM[ES2-T`HD4S?@9!14D/8R@*Y5@"V%_O5['[DNX[ASCR;:&XM
M9V,ES:H*R)(QJ\L*_C1S5GC'>K$L@920I(?Y%G\P7:?P>[]WMU;WG5/M;J7O
M?^`83-[GR4<D%/USO_:=7EH-MYK<"R*)*';54F<K:#)RZ?\`)7>GJ)2D%-,?
M8X]]/;R\YWY?L=RV6/Q-ZV_6R1C/CPR!2ZIY%P55XP/C&I5JQ4$#>PWN-9<B
M\PW^V;Y)X6R;AH5Y#@03QE@C25RJ$,R2$_`=+-10Q&_50UU%DZ*CR6-K*7(8
M[(4M/74%?0U$5715U%5Q)44M91U5.\D%32U,$BO'(C,CHP()!]X!NCQ.\4J%
M9%)!!%"",$$'((."#PZZ#1R)*B2Q.&B8`@@U!!R"",$$9!''J5[KU?JB;_A0
M]T;G>W/Y?M9NS;=%4U^0Z'[.VKVIDZ6DC::H?:K8W/['W!.L"`N\&*_O?!7U
M#_2&EI)9&]*$B>/NZ[Y!M/N''9W$@5+^UD@4G_?E5EC'^V,>@>K,!U`7WD-B
MGW?VYEO+>,L^WW4=PP''PJ/%(?\`:B36?15)Z,E_)S^3FU/DQ\".C)\1E*:?
M=W4&S<!TKV)A/-$V2PV<Z\Q-+M_$5E=`I#+3[IVQ0T>2@E`\;&>2('R0RJ@:
M]Y.5[KECG[?%DB(L;R9[F!O)DF8N0#ZQN61AQ!6O`BHG]EN:K3FGV^V%HIE-
M]90I:SIYH\*A%)'&DB!74\"&IQ!H#V_?Y#OPA[>['[-[=[:_TH[KW_VKV3OK
ML;<%?0[T7;N*HI]Y;FR6>@P>'Q5!BV\.-PE+6I3(\TL\\S1M(S`,(T.MO]_.
M>=GVS:MFVD6<6W6=M%"@:$2,1&@4LS,<EB":"@%:`8J23<?N_<A[SNF[;UN_
MUDNXWEU+,Y68QJ#(Y8*JJ,!11:DDFE2<T%,'\Z3^4_\`$3X1?%7:/;O1&(WY
MC=XY7N[;&QJV3<>\Y=P8V7`9;9N_\U5QBAGQ\)2J^_V[3%)%<:5#`@ZN)F]E
M_=GF_GKFNZV??Y;9K)+*24>'"L;:UDB4=P\J.:C[/3J$_>WVBY.Y"Y2M-YY?
MBN5O7OHXCXDS2+H:.5CVMYU1:'[?7H&NX<'1]_?(S^1?\8^TJVH'2];\/OA[
M43X>>JF@I<O-V)EJRCWA24U0K(U/4;NH]H8[#:XB)$-/&5(95L=;)._+_+7O
MOS1M2K^^UWC<*,`"5\$#PS]D9E>6AQ7)Z)-]MX^8N:/8/E7=F;]QMLVWU6I`
M;QB?$`^<@B2*HS3'6TW\_P#YV]7_`,LWHG9F]LGUMDMU466W'C.M>O\`KO9!
MQ>U\92)0X*NR"QM5FCGH-O;>PN&P_ABCIZ2=@[PQI"(]<D6+/MYR#NON?OU[
M80[DL3I$T\TTNJ0FK!>`.IW9V%22/,D^N5WN-[@[3[6<OV-_-MC3)),L$,,6
MF-112W$C2B(B&@`/DH'F--KYK_S#]J?-CY<?&KY#="_'S</2W>>R=S;:I,ID
MZ'<<&[,IV'FL'NG;^0ZSGCH\+M;`5,VX<+515%)Y&%545E.]+3BR4T:',ODG
MVYON1^4.9N7>8-^COM@GAD(!C:-85:)Q-EV8!'[6H*!64MQ8]85<\^Y-CSUS
MCROS)R]R_)8<P031!B)%D:=EE0P$!$4ET[EJ:EE8+P4#JTKK[9^W/E/_`,*.
M.Y:7OBEI]QXKI6CS>7Z[V?N%8ZK"SUG6.W=J8?95'#C*H&.:GHY<G-N9(5!2
M2M@:9U96D#1;N-W<\J?=MV1]@9HY;XJLTB88">24RFHR"PC6$GB$[0>'4K;;
M9VW-OWF=]3F!%EBL`S0QOE2;>.$1#2<$*9&G`X%^XUSUMV>\/^LR>M._MKJK
M8'1O_"A79O7G6.#QL77OR4VVV)[EZRQD2P[8KL/W=U_NK;O9FW,CBJ0HJXO,
M1QC<<E.=,<55.DB!8TC5<R=HW3<-^^[K?[CNMPYW#;)-5O,Q[PUK-$T#ACQ9
M-;0@\2HH:YZPMWC:MOY?^\C8;;M-N@V[=(M-S`HHA6[AF6="HP%?0LQ'`,:B
MF.DY_+T^0]-_*!^6/SX^(7?.8FCZXV[M[>?:'7DF3JH:)]R[AZ\P53NK9$6&
M21(:2/-=S=7Y"G`52Q?(4M%2J"WM_P!Q>7F]X>4O;_G'88@=SEEC@F"YT+,^
MB753\-O<!B?2-RW#I/[;\QK[,\W^X?)G,$I&UQ123PEC36T*:XM-?Q7-N5`I
MQD0+QZ*=\9MF]I;I^'O\T_\`FE;M>IJ>PM[8?,=2;-S1BE#MD>\>PMJ0=^;E
MPWFU5&-_AFS=XQXRAJ*9K005];"K)XB`+N9KW:;7G/VH]JK,#]VP2)<2)Y%;
M:)_I$8>>N2,RL#Q.@T->@ARO9;M><E>[GNS>D_O.>)[>)Z9#74L?UCJ>(T1R
M+$I'`:QBG6PQ_P`)\.F^MMA_R]-C=F[6HL94;\[JW'OK.]D;CCBC?+3U>UM\
M;DV9M_;D]8RFJBQN$PN#CGBI2WB6IKJB=5!G8G'7[PN];GN'N)?[9=R.+&RC
MB2%"3IH\22/(!PU.S&K<2%4<%'62'W=-DVO;O;BPW2SC0W]]+*\S@#56.5XD
MC)XZ8U047@"S-2K'H_\`_,+Z=ZX[Q^%OR/V7VA0XV?;]'U+OK>-!ELA%"S[1
MW-LO;&5W%M[>-!4RC515F`R-`LK.K+Y:8RP27AED1H_]O-ZW+8>=>6[[:I&%
MP;N*,J/]$21U1XV'F'4TH?.A&0#U(?N-LFV;_P`D<RV&[1J;86<L@8TK')$C
M.DJG\+(P!J/*H."1U3'_`,)@E"?%SY$JIN%[\IU!_J!L/;X!_P!B![FK[T8"
M\T\M@'`V]O\`J_+U!_W5"6Y4YF8C)W%?^T>+I@_X4>?'?IG#]?=<?,G%;UH^
MK?DQMC=FW]H[:7%-44>X.W,?25"Y"E>EEQ9CKJ#<O5ZQBOI\TS(D-':CED,K
M8Q8WONW\Q[W-?[GR9+9-=<L20O(^JA2W)&DUU8*7%?#:+BS$.!025:^\MRWL
M<-AM7.T5\MIS3%,D2::A[D`ZA33D26]/$67@JU0FICH6W_A/3L7K/Y)_(WOG
MY:=\]DMVC\M]LUQRVW]K[L5YLSC:+=,?VN>[DAFJ0*?+U23U?\$I8J55AP$<
MGKC7[O'&(2?>&O\`=.6N6M@Y1V';/I.495TNZ?"3&:K:^JC_`$9M1K,<U.AZ
MAC[N>W;5S/S/S#SAO^Y_5\X1-J1),L!(*/=5X,3_`&*Z12$8H-:4W&O>&_6:
M74:LK*/'4E37Y"JIJ&AHH):JLK:R>*EI*2F@0R35%34SLD,$$,:EF=B%4"Y-
MO=D1Y'6.-"SL:``5))X``<3U5W2-&DD<+&HJ230`#B23@#JMKOOJW*?S$,AM
M;JW)8NNV_P#"O:N\,#OCLS<&7I:C'9WY.YG:M4N4VSUUL/$U*15^*Z9HLPD5
M?F=RU"03YF:GIX,*#3^7(^Y+Y=W>/VX2[W:&19.=Y8'B@52&2Q60:9)I6%0U
MR4)6*%21%5GF(<+'U&',>SR>Y3VFT31-'R-%.DL[,"KWS1G5'!$IH5M0X#RS
M-0RZ52$%"TG5@_\`<G9O_/);8_\`/#BO_J3W'?UMY_RER_[TW^?J1_HK/_E$
MB_WA?\W7_]3?X]^Z]U6_\P_Y4?PN^:W\0S79O6D6U^RJU'([=ZSDIMH[]>I9
M'5*K-314=7@=WRIJ`#9BAKI410L;QCW)7)ONSSKR2([?;-S\7:U/^X\X,D0_
MT@)#1_\`-MDSD@]1ESI[1<C\\F2XW3:_!W5A_N3`1'-_MR`5E_YNJ_R(Z(?U
M%\*OYHG\N2V&^*'=.P?F-\=Z.=Y:;X]]WU57U_N[#T;:Y/L.OMT559D\%MZI
MUL;O_%*3%O*QF?&/(Q(D'=^>/:GW*K/S?L=SLO,C#-Y:@31L?6:/M=Q\]+24
MQXO4=[/R+[M>V-(.3M]MM[Y94XL[LF"1!YB&3N1#\M2QDY\*O1[MG_S*NO<9
M)3X/Y6]1=U?"O=WD@I*B;NS964J>GZS(2@>1-N?(#:='ENKZ_'PN=/GR%5B6
M9AQ'8J6C^^]LMP?7/REO5COED,CZ64"X`_IVDI2X!^2)(/GU(5A[H[='H@YO
MV2_V*])H?JHB;<GAV7D6NW(^;O&?ET>BARO6W<VR*\8G+;,[0ZZWCB,CA,A+
MB,GAMX;1W)@\O1RT.4QL]3CZBOQ63Q^0H*EXIH]3I)&Y!!!]@*2'<MFOD\:&
M:UW&%PP#*T<B,IJIH0&4@BH/D1U($<VV;U8R>#-!=;;,A4E662-U849202K`
M@T(X$'K4P[I_EO?/G^5=WMN7Y+?RRJW</9?3FX))Y<WU;0TDN\-QXG`F::N_
MN;O;K^61JWLO;F,ED=<9E,:LN:I8W8O]O,&JZC+C9/<KD#W6V&WY:]STCMMZ
MC^&=CX:,]`/%BF`I!(U!XD;_`*3GA445</\`?/;+W#]I>8+CF?VL>2ZV23XH
M%'B.J5KX4L)-9XUJ?#D3]9!QH:NS_1?\*5^]-H1C`]K_``+CCWE0JL666A[`
MW9L.(5:76<#;&X>NMUY3&*''"2UTS#Z$\>TLWW9]BNF\?:>?P;)LKJCBE-/]
M/'.JM]H4?9TJA^\_OUJO@;O[?$7JX;3++$*_Z22!V7["Q^WH@'\RS^<9N7^8
MAT)@.CY?BW6=4+@^S\#V.-RQ]AUV\WJ#A-N;NV__``C^%/UYM=8EJ?[U>4S_
M`'#%/!IT'62H^]M/9RV]N^8)]\7FI+O7:O#H\-8Z:WC;5J\9^&BE*>?''4?>
MY_O1<^Y'+T&PGE-[/P[I)M?BM+70DBZ=/@I2NNM:XIPSU9;W)_+YW+\XOY9G
M\OKOOXKYVBG^3?QEZ!ZYV_CZ+%9BGQ60W/%M/#8ILMLNDSDE12I@.P.O=[8N
M>;&"::FB$TU5&[J\D$B1OLGN%;<B>YON'R]S9`1RQN>X3.25U*A=F"R%177#
M-$VF334Z=+`'209,WWVZN>?O:[VZYBY1N`>:=KVZ%5"MH9PBJ6C#&FB>&5=4
M>J@U:U)&H$`6_P#.Z[FV,VP]H?/G^7=_I,[IZ6J<G_`MP[CJ<OU=51YRLQDN
MW,GN>NZ_W'UONS$1[EJ\,\D1K:3P4Q%3,U-!`D@'L]/L=LM[]=><@>XPM=DO
ME&I$T3C0&UJ@E2:-B@8`Z7&K`U%B*]$(]]M[L?H++W"]MC=;Y8DZ'<-`=970
MTAA>&11(5J-2'3W-I"@TZ$K!?\*..N<=F,=61_RWH\&8*N$ME\-V)@QE<?$S
MA)JJA"=(XYGJ(HF)5?/"'/!=0;@LE^[?N$T;Q-[FJX8<'B;2?35_C+8KQ-#3
MC0\.C.+[R^VPR)*OM@RE3Q25-0]2O^++FG`:A7A4="+_`#`OBGW/V-V5TU_.
M3_E@55;NC>N7VKM'>&\=F;>IJ:MW?D!3[:IL/39JFVQ')4?WDJJK9SC;NZ=N
M)KK4-,RK#.9:OP%_MYS7LFW;9O7LS[I(L-DDLD<<CDB,5?44,E/TZ2#QK>?X
M,Y(&FIC[C<H[[N6Z;)[U^U+M->O#'))$@#2&B:0XCK22L9\&X@^.BX!.J@>'
M_A1Q\FSA/]'J?`5Q\@RG\+"?Q[?+8<9SQ^+S?Z*O[F#>!_RSC[#^.^6W'GO[
M,?\`@;>6?J?KS[@#^KWQ?##KT_\`-?Q?"X?C\.GGI\NB[_@F.:/I?H![>'^L
M?P_%/HU<*^!X/B\?P>)7RU>?1B_Y37\OKY+[C^2>[OYFOSZI\AC>Z=W+F)^M
MMB[BI8Z'<V)J]QXIMNUF[<_@E5/[FT>&V<[X7!X614GIZ25VDAIU@I?*'/=S
MW"Y8MN6;+VP]OV1]EAT^-*A)C(1M8C1_]%+2?JS2_"S@!2>Z@D]G_;KFJYYG
MO?=+W#5TWN8-X$3BD@+KH,KH,1!8_P!*&+XE0DL`=-0A_P"%'?P<W%V+E^@?
MDWU3M>MSVZ\SF\3\>-\XO"TIGR&4JL_7U5;U1D?#%H3R29.IR&)FJ)>7DJ,=
M!J`"CV;_`';N=K:QAY@Y6W:[$=I'&UY$S&@4(H^I45Q\`60`<=#^O1/]YCD:
MYOYN7>:]HLS)>22+92JHJ6:1B;9C05^,M&6/#6@\NKS^EO@OUEUY\"MO?!C<
M-%%DMF573^0V!V'58PBFFS6Y-XT576[]W7C*B2-I*2OJ=W9:JKZ"1@STC+"!
M_FE]P3O?/>Z;CS]<<^6TA2^%X)H0>")&0(HR*_"(U5&'F*^O4^;'R#M6W>WU
MMR#<QA[`V1AF(XN\@)FD!I\1D9G4TP:>G6M!UWO;^8O_`"$MZ;[ZTR_3E9\D
MOB'N/<=9N/;N<Q\&;I=JO/((*2/<.%W?B,?N$]9[GRF+I8(LIALM3543RTVJ
MG61`*V;)S<K'VX]_K&QW2#>5VSG"*((Z$IX@`SH:-V3QXU8GPY8V#!31Z'M&
M+FVW_N7]WR^OMJGV5MTY-EE+HZA_#).-:2(K^!(R@"6*12I8:DXZCP^0_P#,
MD_F'?S9MDYOXV_$_XC[JZ]Z\W11S)V5D\+D,GNO)9K!4*QUM1@<SV3E,#LC:
M6TL!7R0Z9Z(1BLREEI4FD2:2EGUR[[:^WGM)>0<S\V<WPW.Y1-^@&"HJ.<!U
MA5Y))'6M0Q[(_C(J`PWS'[F^XWO!9S\K<H\G36VV3+^NREG9T&2CSLD44:-2
MA45>3X`:$J1\_P"$_O?_`$]\6OB?\M)OD!OS"]65FQ^UZ/=&?P&ZWFQ^Z1B9
M-I4.'I_X5M>2'^/9[(568PU11QT=%3U%4U2@C\89T#!_[P?+V\\S\U\G1[!8
MM=K-9F-7C(:/5XKMW2`Z%`5E;4S!=)K6E>A#]W7F/9>5^4N<Y.8+Y;1H+T2,
MD@*R:?!1>V,C6[%E9=*J6U"E*TZ"/ISKSL_^?!_,%RG?7<>WMP[6^$GQ^KH*
M+;NSLM'54E'E<#3USU>!Z\I71OM:C=G8%12C);MJJ5Y7I*'_`"99XQ_"B#G>
MMQVKV$]O(N7]FN8IN>-P4EY%(8AR*/,?2.$$QVRD=SUD(^,=$NR;=NWW@/<:
M;F'>K:6'D7;F`2-@5#(#5(!ZR3$"2Y8'M2D=?@/0N?S+?@1W7\'/E!L/^8M_
M+CV5E5II]TTB]D=0]<[8KLK283<>4;[6O>GV7MJG,U;UAV?2R24F3HH(XQC\
MC,3"\8JJ849/[8\_;'SURMN'MO[CWJ:A"?!N)G52Z+D5E<T%Q;GNC9CWH"K5
MTG6<>Z/M]OG(7->W^YGMK8OI,P\:WA1F".W::11BIM[@=DJ**1N0ZTU#1?3T
M;\B_D[WIM?#9BJ^&VZOCW+7XVDFR5;W[OK;N.6AKY(8'K(L-LO:<><W_`)6*
MFE=UC7,4>V'ETW)3FT![_P`M\K[!=SP)SK#N05CI%I%(:CRU22Z(E/KX9F`\
MJ]9!<O\`,W-7,%I!/)R/-MC,HU&\EC%#YZ8XM<K#T\18"?.G1PH<"U=BX*+>
M#XW=%0M0M9.7P\-)B?N4;5#]KB9ZC)>.&E;F+SS5$JL`VLL`0#6G"2L]F&B6
ME!W5:GS8`9/G0`>5.AJMN9(@EX5E:M3V@+7RHI+</*I)^?3Q)D*"*J2AEK:2
M.MEB\\5')4PI520>9*?S)3LXE>+[B54U`6UL%^I`]LB.0H7"$H#2M#2O'C]F
M>GC)&'$9<!R*TJ*TK2M/MQ]O47^.X3_G<XK_`,^%)_U^]V\"?_?+_L/5?'@_
MW\G[1U__U=_CW[KW7O?NO=>]^Z]UPDCCEC>*5$EBE1HY(Y%5XY(W4JZ.C`JZ
M.I(((L1[V"000:$=:(!!!%0>@*J/C#T$^:;<N,ZMVQM'<\DK33;GZ[@J>M-R
M54S-K:6NSW7]3MO+5[EN?WYI/9\O-',`@^EEW66:UI0),1,@'R24.H_(#H@;
ME7EXSFZBVF*&Z)J7A!@<GYO"48_F3T(>$VA5[?TQ4>\MW9"C5@5HMQUU'N$*
M@L-`R>0H&S\G']J2LD/Y-S[+9[Q+BI>RA5_5`4_XR#H_8HZ,H+)[:@2]F9/1
MR'_XT1K_`&L>EFR(_P"I%:WTU*#;_;@^T8)'`]+2`>(ZX^&'_CE'_P`D+_Q3
MW[4W\1Z]I7T'7DBBBU>.../6VM]"*FM[!=;:0-3:5`N>;#WXDFE37KP`%:"G
M7)D1[:U5K?34H:W^M<'WX$C@>O$`\1UQ\,/_`!RC_P"2%_XI[]J;^(]>TKZ#
MKN.*.(%8HTC5F9R(T5`78W9R%`!9C]3]3[\23Q->O``<!3KEI%]5AJMIU6%[
M7O:_UM?WKY>76_GUW[]U[KH@'Z@'D'D7Y!!!_P!<$>_=>Z[]^Z]U[W[KW70`
M4`*``/H```/]8#CW[KW#K`])2RR)-)34\DL98QRO#&\D9868H[*64L.#8\^[
M!V`(#&AZJ44D$J*CK.`%`"@*!]```!_K`<>Z\>K<.'7?OW7NO>_=>Z][]U[H
MK_;GQ6V?W#O>CWSFMS[OV_E*#&[?I:-]J38;'5=-D=I[@.Z-L9B')U>'R%8E
M3@\YIJH%O99XU-_&9(Y!/M/--YL]B]C#:PR1,SD^(&((D30ZZ0P%&7M/R/K0
M@+;QRI9[S?)?SW4T<JJ@'AE008WUHVHJ356[A\P/*H)#/^&-/A=_QU[-_P#0
MCPW_`-C?L>?Z^/.G_+M_O#?]!]`/_6,Y+_BNO][7_H#K_];?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54OS@^<&[OCA\L/AUU/MS'[WSVQ
M][8ON+L#OG!]8]4Y/M[?]3LO:^%QN,V!!B-OX+'Y'-8Z@RF^:R2.LK8%C\,4
M5RYMH:6^1.1;3F7E'G7=[EH$O8&MH;1Y[A;:%99'9Y2SN51B(4.E"<DX&.H@
MY^Y]N^6.<.2-GMEN'L9UN9[M(+9KF9H8T5(@J(&=09G&IP,`9.>B=;*_F.?(
MWO+?>S(^LMPC:FV>[?YEM-T!UMMC=_6F)QN[\-\:NE>NX=V?('(5V,RU(<G3
M[GRM9FZ&,M7!ZG%2PSQCQD:0-+_VTY:V+;[T[E;>)>;?RL;RX=)RT;WMU<&.
MS",ITF-4[J*=,@S4@]`G;_<[F??MQLOW9=>%9;CS6+.V1X`LB6-K;^+>%U<:
MA(S]M6[HS5:`CI7?'?YT?*/OS;'Q%Z,Q&\-K#Y([O[0[TW1\IM_4VU-MRT'7
M'QNZ#[>W;LNMJI]I%1C,!N#LJHBQN!P]6T$R1U4,\LB>H2A%S#R#RKR[<\X[
M]=6<IY;AL[1+&'Q'K/>WMM'*HUUU,D`,DT@'EH2N>EO+?N#S9S):\F;!;7D0
MYFGO;Q[^81I2"QLKJ2%CX=-"O<,(X8R?/6],=+S-_P`P#L_$?%S,=RTFZ=HM
MV%\QOD=N_K7X`[<W;2XC;&V]I=5KF8MB[/[-WW5U-+%4U6V:'";=K]^Y*OKS
M40F/+4-`&2*6'V6VWM[M<_-46S2VLPVS9=LCGW9XR[N\VGQ)((AD"1GD2SC5
M0*,CR'@QZ,[KW%W6#E.7>HKN$[IO>YR0;0D@1(XX-7A1SRG!:-4C>]D9B:JZ
M1BE5'2*ZW_F#=[=D=(?RQ11;RVG1=O\`R*^1N_\`;/?.:7;V"JL9D^H_C5E=
M_P`O><F$HEC&,P;Y;;6`H*J.OID4TL$WDC"ZK!?N?MYR_MV^^ZC/93#9MMVR
M*6SC+MJ$][X`M0S?$^EI&!4_$5H>B_:_<;F'<=A]IU6]A.];GNDT5Y((UTF"
MQ\<W95?A34L:$,/A#5'03;$^9WS]QW1/Q^^>6[NYNO-R=/\`?WR0P_7%#\5,
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MMBO]KN(C(VZ067AG4&4SQR2"9C0J(D6)RY)J`I-*=2=S/[A;3REN4UANMM*(
MTVJ>^\0:2K""2.,PJM0QF=I4"`"A+`5KT`.^OYIV&ZT[+ZRZXWUT#N_:]?O?
M*]&[7W%29?M3I"GWQM;>/>T6$;$8/#=5IOF7?V_:79-7GX:/<-=14D5/15D4
MR0_<I&)&/K#VIFW3;-TW*PYB@EC@2[D0B"Y\*2*TU%G:<Q"*(RA"T",Q9P5U
M:"P'0?W#W:AVK<]KVW<>7)XI)WM(W#3VOBQRW>C2BVXE,THA+A9W50J'5IUA
M2>E)@?YF>WLX,QV2/CYW3'\0\?-VU347R[HHMJYW8%8O2])N.3=NX:_9^%SE
M;O\`P.Q,GD]J5F-PV7J:()D<CXX#%"7)1/<>U]S#X&V#F*Q;G)Q;$[=619A]
M44\-%D91$\RK(CRQ*U40DU.DCI1;^ZEK/X^Z-RW?KR6AN0-QI&T)^E#^)(T:
MN9DA9HW2*5DI(X`H-0/0:]C?S*=]8_XZ=E=FY[XO?)#X^IE>LMF;QZ'WY78/
MK'L:+=Z=L;UVSU[L*"+'T>ZZK:^`[0_B&\:3*?W3SM1'4_PV*:66PC*,9[9[
M9[?)S)M6VP<T[;N6B[ECNX5:>$QBWB>:8ZC&'>WTQNGU$0(UT`&0>BW=/<_<
M(^6=VW.XY4W/;-=I%):3,MO,)#<RI#"H42E$N`TB/]/,0=%23@CIZQO\T/'8
MSL/;G7&2Z.[:W%LU/EJWP4S/R,DK>ML1M;,]Z8B&2CR>5QVRJ;<0W34[>%7B
M<A69*JIJ%,=BZ6G:TSRD4X32^UDDFVW.Y)OUG%>_N<;HMG2=I%MF;M5I#'X8
M?2R:`SEI-0P./2B+W6CCW.VVQ^7[R6Q&\_NIKW5`L;72J=3K$)/$*:E?Q"J!
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MDL`KSUR)+R-<6UI<;JD]TS.K)X,\+H4(&L"9%$D,E3X4T;,KT-0OF+>0^?8N
M>[>YN[?:7@M45&63QH)T?6"=!,+L8YXZ4EAD560D4+5P>SV`>I`Z][]U[KWO
MW7NO_]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54K?9_\
M/8+K^T_B?_#:\OV_\:_CW\2_AW^S&1>;^X_V_P#OTOL/N[?Q3[K_`'*>7Q^/
M_)M7N6!J_P!9$TU>'_685TZ=-?HS3QJ]]:?V6GLIKKW4ZB,Z/]?,5T^)_5@T
MUZM5/K,^#3LI7^UU=]=%.VO57OP:_AG^G7^5M_Q[7G_TF?S6?M/[U_WO_OA_
M$/NY/XA]S_R[_P#3C]GI_COWW^XS^`_;?9?Y5Y/<K^X'C?N+W1KXE/I.7JZ?
M"TZ?"&G33/TG^^]/ZGB?VN.HD]O/!_?_`+5:?#K]9S'35XM=7B]VJN/K/]^:
MOT_"_LL],'P9_AGC_GG?P/\`NA_%M??OWW^A+^]O^S%?9_QSNG[?^Y'^D3_?
MD_W3O]W]E_#O\N_C-_-Q_#?;W/WBT]A?J?&\'3:T^I\/Z/X;6OB^!^KXOPZ]
M>/`T:?\`1.F?;_PJ^_\`]-X/C5NZ_2^)];\=U3P?'_2\+XM&C/CZZ_Z'UQ[^
M_@W]^O@Q_P!N^K_\-V;%_NQ_L_/]_?\`9$?X)]EL/S?[*I;T_P![/+;^)?WO
M_P!_#_`_L/%^WJ]TV#QOW5SW3^L'_*RR>)^Z_"_>FK]:GU]?]#X^']-^EXOB
MZ\Z>K\P>!^]>0?\`E7?^59C\/]Z^+^ZM/Z-?W?\`\,X>)]3^MX7A:,:N@%Z$
M_A7\.Z5T_P"COQ?W+_G1_P`+_P!$W]\O]&OD_P!&]%]]_LFGE_ROP?;?7^,_
MM?PGQ_:?O^Q'S+XW^[ROC5\;EC5X_A?44U-I^OIC_3>'GQ:>)CH-\L^!38:>
M#3P>:=/T_B_3UTKJ_=]<_P"E\3'A5\/I8?#/^Z/\8_EP_P`3_P!+O\:_O)M;
M^Z?^S\?Z;_\`95-7\.D\W^R'?W1_WX/^D/[/R_P+^^OI\OV_B_RG[;VFYW^M
MT>Z_A?2^!ID\3]U_2?O#^T%/WMXGZW@5_MOI,:OB[*]*.1?H?$]I?%^J\>L?
MA?O7ZO\`=_\`9Y_='A_H^/3^Q^KSI^'OIU'^-_\``_M/@%_S-S^XO^SM;<_N
M3_I1_P!(?_#6_P#'/[\;W^T_V3__`+F,_P!+7GO_`'+_`-(7^_=_C?\`%ON?
MV=/MOF;ZC_D?_P"X'[P_<;>+X'@_OS1X4'^Y_P#Q"\'A]5]%_C'AZ//5T]RQ
M]/\`\P]_Y*'[O_?R^%]1XW[B\3Q9_P#DG_\`$WQ^/TOUO^+>)K\M/5@G\VS^
M!_[/1_*[_BW^B3S?WXW9]E_I6_TB?W:^Z_TE]#_8_P!ZO[E?[C_X1_$_#_"?
MXA_D?]X_L_N_\@^Z]Q][0_4?U#]UO!^KT_3)7P/!UT\&ZKX?B]VNE?$\/N^G
M\71WZ>I#]X_I_P"OWM+XWT>KZF33]1X_AU\:UIXGA=NBM/"\3M^I\'7V:NB$
M1:?]G9W-XOXE_=7_`(?1VY_#OXIY?]"O]\=;_P!X?XS]W_QF;_31]UX_X1_%
M/]^)Y-/\$_R?S^QVU?ZCVOP?5?U$?52GU/AZAHT?\1_IZ?VGA?XU35X^:=`(
M4_KW<_VGTG]?4TUK]+XFGOU_\2/J/]]^+_BFK3X&*]8^F_[I_P"RL9[^-?W[
M_N;_`*"_G+_<;_2)_IJ_X;H_AOWN_O[U_P"RQ_W`_P",\:?M=?W'^D7_`'+?
M<^?^[G^4>'V]N?UO];+'P/IOK/WCM/B_3_2_OK52/POJ_&_Q6O\`SQ_I?!]7
MY])]K^B_JC?>/]3]%^[=W\+ZCZO]R::R^+]'X/\`C5/^>W]7X_H_+H5*7[7^
MXW1?\8_V:S^._P"G;^6[J_V=3^,?:_W7_P!(2_W8_N[_`'%_XQS_`++_`.6V
MC3_O\?X]]O\`Q_\`;O[+1XGUN]?3_NGZ;]W[Y_R2]%?$^F_5\3QOU_J:?%7_
M`!;P=?TG=7HS/A_1;)]1^]OJOWCL7_)4UZ?#^I_2\/P/\7^EK\-/\9\;P_K.
MVG0C]._8?P/^7YY/X);_`(<5^=?E_OY_>/[/^)>'NV_^EO[;U?Z:?K]IX?\`
M<3XO);\>T&]^-X_N1_:_\JMM']GX5=-;&G@?\NO"O^C?#J_%T8['X/T_MI_9
M?\K7O']IXM-5+ZOU'_+UQI_H/Q:?P=!)\.O[N?Z(Z'^,_P"S;?W9_P!ET[1_
MT>_W0_TJ?Z-OX'_>G_*?]DJ_N'_QEW^/??\`A_@_^D__`'\7\*U>#_(_NO9G
MSI]5^_)?I_W/]7^];?QO&^G\?7I.G]Z^/_BVFE?&^B_Q?Q/[3OT=%7)'TO[B
MB^I_?/TG[IN/!\#ZCP/#UC5^ZO`_QG56G@_7?XSX?]GV:^CW_P`HO[O_`&8C
M^8K_`'D_B?\`?S^]/QW_`+Q_Z3OX+_LR'\,_N%NK^Z_^FK_11_SC=YOL-?\`
M#_[J_P"Y?R_>?W@_RSQ>X[]WM']7O;CZ;3]!X-WH\'5]'7QDU_3?4?XY2M-?
MC_ITT?3]E>I']G=?]8_<GZK5^\/&L]?CZ/K=/@OH^I^G_P`2K3X/I_U*Z_J.
3^G5Z_N">I\Z][]U[KWOW7NO_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
